Health Canada has approved Livmarli (maralixibat) for treating cholestatic pruritus in patients aged 12 months and older with progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).
PFIC is a rare liver disease that affects bile flow. This can cause bile acids to build up in the liver, leading to severe itching. Many patients, especially children, experience a significant impact on their quality of life due to this condition. Livmarli aims to alleviate this itching, offering hope for both patients and their families.
The drug comes in two forms: a 19 mg/mL oral solution and a tablet for those weighing 22 kg or more who can swallow pills.
Recent data highlights the rising number of rare diseases like PFIC. According to the National Organization for Rare Disorders, about 1 in 10 Americans is affected by a rare disease, showing the urgent need for effective treatments.
Experts emphasize that advancements in rare disease research are crucial. Dr. Sarah Jones, a pediatric hepatologist, explains, “We’re finally seeing significant progress in the treatment of rare diseases, which could lead to better outcomes for patients.”
With the approval of Livmarli, there are glimmers of hope for improving the lives of those affected by PFIC and ALGS. For more details, you can check statistics on rare diseases from Global Genes.
